Aetiology of Heart Failure, Rather than Sex, Determines Reverse LV Remodelling Response to CRT

Introduction: Cardiac resynchronization therapy (CRT) is an established therapy for patients with heart failure with reduced ejection fraction (HFrEF). Women appear to respond differently to CRT, yet it remains unclear whether this is inherent to the female sex itself, or due to other patient characteristics. In this study, we aimed to investigate sex differences in response to CRT. Methods: This is a post-hoc analysis of a prospective, multicenter study (MARC) in the Netherlands, studying HFrEF patients with an indication for CRT according to the guidelines (n = 240). Primary outcome measures are left ventricular ejection fraction (LVEF) and left ventricular end systolic volume (LVESV) at 6 months follow-up. Results were validated in an independent retrospective Belgian cohort (n = 818). Results: In the MARC cohort 39% were women, and in the Belgian cohort 32% were women. In the MARC cohort, 70% of the women were responders (defined as >15% decrease in LVESV) at 6 months, compared to 55% of men (p = 0.040) (79% vs. 67% in the Belgian cohort, p = 0.002). Women showed a greater decrease in LVESV %, LVESV indexed to body surface area (BSA) %, and increase in LVEF (all p < 0.05). In regression analysis, after adjustment for BSA and etiology, female sex was no longer associated with change in LVESV % and LVESV indexed to BSA % and LVEF % (p > 0.05 for all). Results were comparable in the Belgian cohort. Conclusions: Women showed a greater echocardiographic response to CRT at 6 months follow-up. However, after adjustment for BSA and ischemic etiology, no differences were found in LV-function measures or survival, suggesting that non-ischemic etiology is responsible for greater response rates in women treated with CRT.

[1]  M. Vaduganathan,et al.  OUTSTEP‐HF: re‐evaluating the role of physical activity measures in drug and device development in heart failure , 2021, European journal of heart failure.

[2]  M. Rienstra,et al.  Heart Size Corrected Electrical Dyssynchrony and Its Impact on Sex-specific Response to Cardiac Resynchronization Therapy. , 2020, Circulation. Arrhythmia and electrophysiology.

[3]  H. Heidbuchel,et al.  Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care , 2020, European journal of heart failure.

[4]  P. Vandervoort,et al.  Withdrawal of Neurohumoral Blockade After Cardiac Resynchronization Therapy. , 2020, Journal of the American College of Cardiology.

[5]  N. Samani,et al.  Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study , 2019, The Lancet.

[6]  S. Solomon,et al.  Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. , 2019, JAMA.

[7]  G. Plank,et al.  Sex-Dependent QRS Guidelines for Cardiac Resynchronization Therapy Using Computer Model Predictions , 2019, Biophysical journal.

[8]  Jeroen Dauw,et al.  CRT Optimization: What Is New? What Is Necessary? , 2019, Current Treatment Options in Cardiovascular Medicine.

[9]  J. Voigt,et al.  Sex-specific difference in outcome after cardiac resynchronization therapy. , 2019, European heart journal cardiovascular Imaging.

[10]  R. Kim,et al.  Size Matters: Normalization of QRS Duration to Left Ventricular Dimension Improves Prediction of Long-Term Cardiac Resynchronization Therapy Outcome , 2018, Circulation. Arrhythmia and electrophysiology.

[11]  L. Jordaens,et al.  Gender differences in electro-mechanical characteristics of left bundle branch block: Potential implications for selection and response of cardiac resynchronization therapy. , 2018, International journal of cardiology.

[12]  M. Gold,et al.  The interaction of sex, height, and QRS duration on the effects of cardiac resynchronization therapy on morbidity and mortality: an individual‐patient data meta‐analysis , 2018, European journal of heart failure.

[13]  G. Hindricks,et al.  CRT Survey II: a European Society of Cardiology survey of cardiac resynchronisation therapy in 11 088 patients—who is doing what to whom and how? , 2018, European journal of heart failure.

[14]  I. V. Van Gelder,et al.  Refining success of cardiac resynchronization therapy using a simple score predicting the amount of reverse ventricular remodelling: results from the Markers and Response to CRT (MARC) study , 2018, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[15]  G. Mascioli,et al.  Magnitude of QRS duration reduction after biventricular pacing identifies responders to cardiac resynchronization therapy. , 2016, International journal of cardiology.

[16]  R. Nijveldt,et al.  Improved patient selection for cardiac resynchronization therapy by normalization of QRS duration to left ventricular dimension , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[17]  Jagmeet P. Singh,et al.  QRS Duration or QRS Morphology: What Really Matters in Cardiac Resynchronization Therapy? , 2016, Journal of the American College of Cardiology.

[18]  Jeroen J. Bax,et al.  Cardiac Resynchronization Therapy in Non-Ischemic Cardiomyopathy. , 2016, Journal of atrial fibrillation.

[19]  P. Vardas,et al.  РЕКОМЕНДАЦИИ ПО ЭЛЕКТРОКАРДИОСТИМУЛЯЦИИ И СЕРДЕЧНОЙ РЕСИНХРОНИЗИРУЮЩЕЙ ТЕРАПИИ.ESC 2013 , 2015 .

[20]  J. Ottervanger,et al.  Apical rocking is predictive of response to cardiac resynchronization therapy , 2015, The International Journal of Cardiovascular Imaging.

[21]  Kevin Vernooy,et al.  Strategies to improve cardiac resynchronization therapy , 2014, Nature Reviews Cardiology.

[22]  P. Vandervoort,et al.  Comorbidity significantly affects clinical outcome after cardiac resynchronization therapy regardless of ventricular remodeling. , 2012, Journal of cardiac failure.

[23]  Arthur J Moss,et al.  Predictors of super-response to cardiac resynchronization therapy and associated improvement in clinical outcome: the MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy) study. , 2012, Journal of the American College of Cardiology.

[24]  S. Solomon,et al.  Predictors of Response to Cardiac Resynchronization Therapy in the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy (MADIT-CRT) , 2011, Circulation.

[25]  P. Vandervoort,et al.  Importance of adjunctive heart failure optimization immediately after implantation to improve long-term outcomes with cardiac resynchronization therapy. , 2011, The American journal of cardiology.

[26]  S. Solomon,et al.  Cardiac resynchronization therapy is more effective in women than in men: the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy) trial. , 2011, Journal of the American College of Cardiology.

[27]  F. Leyva,et al.  Female Gender is Associated with a Better Outcome after Cardiac Resynchronization Therapy , 2011, Pacing and clinical electrophysiology : PACE.

[28]  Wojciech Zareba,et al.  Cardiac-resynchronization therapy for the prevention of heart-failure events. , 2009, The New England journal of medicine.

[29]  Claudia Stöllberger,et al.  Guidelines for device-based therapy of cardiac rhythm abnormalities. , 2009, Heart rhythm.

[30]  N. Freemantle,et al.  The effects of aetiology on outcome in patients treated with cardiac resynchronization therapy in the CARE-HF trial , 2008, European heart journal.

[31]  David L Hayes,et al.  Sustained Reverse Left Ventricular Structural Remodeling With Cardiac Resynchronization at One Year Is a Function of Etiology: Quantitative Doppler Echocardiographic Evidence From the Multicenter InSync Randomized Clinical Evaluation (MIRACLE) , 2006, Circulation.

[32]  J. Daubert,et al.  The effect of cardiac resynchronization on morbidity and mortality in heart failure. , 2005, The New England journal of medicine.

[33]  J. Conti,et al.  Ventricular Reverse Remodeling and 6-Month Outcomes in Patients Receiving Cardiac Resynchronization Therapy: Analysis of the MIRACLE Study , 2005, Journal of Interventional Cardiac Electrophysiology.

[34]  D. DeMets,et al.  Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. , 2004, The New England journal of medicine.

[35]  W. Tang,et al.  Profound differences in prognostic impact of left ventricular reverse remodeling after cardiac resynchronization therapy relate to heart failure etiology. , 2018, Heart rhythm.

[36]  M. Costanzo Cardiac Resynchronization Therapy in Women. , 2017, Heart failure clinics.

[37]  Guangyou Duan,et al.  A prospective observational cohort study , 2016 .

[38]  E. Corrado,et al.  The QRS narrowing index for easy and early identification of responder to cardiac resynchronization therapy. , 2014, International journal of cardiology.

[39]  J. Nielsen,et al.  ESC Guidelines on cardiac pacing and cardiac resynchronization therapy , 2014 .

[40]  M. Link,et al.  2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. , 2013, Journal of the American College of Cardiology.